Intronic variant near the ATM gene affecting metformin's activation of AMPK; the C allele confers improved glycemic response to metformin and links the DNA damage response pathway to longevity-relevant AMPK-mTOR signaling

Promoter insertion variant in APOC1 that increases gene transcription by 50%, raising apolipoprotein C-I levels and strengthening CETP inhibition to produce higher HDL-cholesterol and lower triglycerides.

Intronic variant in the BDNF-receptor trafficking gene SORCS3, associated with mood instability, neuroticism, reduced wellbeing, and cross-disorder psychiatric risk across multiple large GWAS

Regulatory variant near the NPR3 transcription start site that reduces natriuretic peptide clearance receptor expression in vascular smooth muscle and endothelial cells, raising blood pressure by impairing ANP and BNP removal from circulation

Pathogenic missense variant in muscle glycogen phosphorylase causing post-translational protein loss; homozygous or compound heterozygous carriers develop McArdle disease (glycogen storage disease type V), the second most common PYGM pathogenic allele in Spanish populations

Intronic SLC2A9 variant tagging an independent urate-transport signal; the protective C allele (~26% global frequency) reduces serum uric acid by 0.23–0.46 mg/dL per copy — with a substantially stronger effect in women — and attenuates the hyperuricemic response to fructose; the major T allele confers elevated uric acid and increased gout risk, particularly in Europeans

3' UTR variant in the type 1 deiodinase gene associated with markedly increased cardiac mortality after myocardial infarction, acting through reduced local T4-to-T3 conversion in cardiac tissue

Pathogenic missense variant in the ZIP4 intestinal zinc transporter causing hereditary acrodermatitis enteropathica when homozygous; heterozygotes are asymptomatic carriers

Nonsense variant in sepiapterin reductase creating a premature stop codon (p.Lys251Ter) that abolishes BH4 synthesis, causing dopa-responsive dystonia with severe neurotransmitter depletion when inherited biallelically

Pathogenic PROS1 missense variant in the fourth EGF domain of protein S; heterozygous carriers have reduced free protein S activity and a markedly elevated risk of venous thromboembolism consistent with autosomal dominant type I protein S deficiency